SAN FRANCISCO--(BUSINESS WIRE)--
Invitae
Corporation (NYSE:NVTA), a genetic information company, announced
today the closing of its initial public offering of 7,302,500 shares of
common stock at an initial public offering price of $16.00 per share,
which included 952,500 shares sold pursuant to the exercise in full by
the underwriters of their option to purchase additional shares of common
stock. Total gross proceeds from the offering were approximately $116.8
million, before deducting underwriting discounts and commissions and
other offering expenses. All of the shares in the offering were offered
by Invitae. Invitae’s common stock is listed on the New York Stock
Exchange under the symbol “NVTA.”
J.P. Morgan Securities LLC acted as the sole book-running manager for
the offering. Cowen and Company, LLC and Leerink Partners LLC acted as
co-managers.
Registration statements relating to these securities have been filed
with the Securities and Exchange Commission and became effective on
February 11, 2015. Copies of the final prospectus relating to the
offering may be obtained from J.P. Morgan Securities LLC, Attention:
Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY
11717, or by telephone at (866) 803-9204.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there be any
sale of these securities in any state or jurisdiction in which such
offer, solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About Invitae
Invitae’s (NYSE:NVTA) mission is to bring comprehensive genetic
information into mainstream medical practice to improve the quality of
healthcare for billions of people. Currently focused on hereditary
cancers, Invitae’s goal is to aggregate most of the world’s genetic
tests into a single service with higher quality, faster turnaround time
and lower price than many single-gene tests today. The company currently
provides a single diagnostic service comprising over 200 genes for a
variety of genetic disorders associated primarily with cancer, but also
covering cardiology, hematology, neurology and pediatrics.
Source: Invitae Corporation